- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00060632
Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)
A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Weekly Administration of AP23573, an mTOR Inhibitor, in Patients With Refractory or Advanced Malignancies
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The primary objectives of the study are to determine the safety, tolerability, and MTD of ridaforolimus when administered once weekly for 4 weeks (4 week cycle). The secondary objectives of the study are to characterize the pharmacokinetic profile of ridaforolimus, to evaluate potential pharmacodynamic markers of ridaforolimus, and to obtain preliminary information on the antineoplastic activity of ridaforolimus.
Protocol Outline: This is a dose-escalation study. Patients receive ridaforolimus over 30 minutes by intravenous infusion once weekly for 8 weeks (two 4-week cycles). If tolerated, a total of at least 2 cycles will be administered (8-week treatment period). Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
(Patients must meet each of the following criteria to be eligible for participation in the study).
- Male or female patients, ≥ 18 years of age.
- Patients with a documented measurable or evaluable malignancy, including myeloma or lymphoma, that is recurrent, advanced, or metastatic.
- Patients with disease that is currently refractory to, or not amenable to, standard therapy.
- Patients with disease that is currently not amenable to surgical intervention.
- Patients with Karnofsky performance status of ≥ 70% (Eastern Cooperative Oncology Group [ECOG] performance status of 0 or 1) and an anticipated life expectancy of ≥ 3 months.
- Patients either not of childbearing potential, or agreeing to use a medically effective method of contraception.
- Patients with the ability to understand and give written informed consent.
Exclusion Criteria:
(Patients meeting any of the following criteria are ineligible for participation in the study)
- Women who are pregnant or lactating.
- Patients with primary central nervous system (CNS) malignancies. Patients with leukemia, any form.
- Patients with certain hematologic abnormalities.
- Patients with certain serum chemistry abnormalities at baseline.
- Patients with known or suspected hypersensitivity to either drugs formulated with polysorbate 80 (Tween 80) or any other excipient contained in the test drug formulation.
- Patients with known hypersensitivity to macrolide antibiotics (e.g., clarithromycin, erythromycin, azithromycin).
- Patients with significant cardiovascular disease.
- Patients with active CNS metastases (or leptomeningeal disease) not controlled by prior surgery or radiotherapy. Note: Patients with treated brain metastases will be eligible if they are on a stable dose of corticosteroids or are without change in brain disease status for at least 4 weeks following related therapy (e.g., whole brain radiation, surgery).
- Patients with known human immunodeficiency virus (HIV) infection.
- Patients with any active infection.
- Patients with inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure within 2 weeks prior to study entry. Note: Patients having undergone recent placement of a central venous access port will be considered eligible for enrollment if they have recovered.
- Patients who have any other life-threatening illness or organ system dysfunction which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with evaluation of the safety of the test drug.
- Patients with a psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary studies.
- Patients with the inability, in the opinion of the Investigator, to comply with the protocol requirements.
Drugs and Other Treatments to be Excluded (Either during or within 4 weeks prior to study entry, unless otherwise noted)
- Chemotherapeutic agents (standard or experimental).
- Other antineoplastic agents.
- Immunotherapy (including vaccines) or biological response modifier therapy.
- Systemic replacement hormonal therapy for life-threatening non-oncology diseases.
- Herbal preparations or related over-the-counter (OTC) preparations containing herbal ingredients (e.g., St John's Wort) during or within 2 weeks prior to study entry.
- Any prior therapy with rapamycin, CCI-779, or any other rapamycin analog.
- Any other experimental therapy during the course of the study.
- Radiotherapy for the primary malignancy or metastases.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Cohort 1: Ridaforolimus 6.25 mg
|
Administered intravenously once weekly for 4 weeks (1 cycle). In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles.
Andere namen:
|
Experimenteel: Cohort 2: Ridaforolimus 12.5 mg
|
Administered intravenously once weekly for 4 weeks (1 cycle). In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles.
Andere namen:
|
Experimenteel: Cohort 3: Ridaforolimus 25 mg
|
Administered intravenously once weekly for 4 weeks (1 cycle). In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles.
Andere namen:
|
Experimenteel: Cohort 4: Ridaforolimus 50 mg
|
Administered intravenously once weekly for 4 weeks (1 cycle). In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles.
Andere namen:
|
Experimenteel: Cohort 5: Ridaforolimus 100 mg
|
Administered intravenously once weekly for 4 weeks (1 cycle). In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles.
Andere namen:
|
Experimenteel: Cohort 6: Ridaforolimus 75 mg
|
Administered intravenously once weekly for 4 weeks (1 cycle). In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Maximum Tolerated Dose (MTD)
Tijdsspanne: Cycle 1 (within the first 4 weeks)
|
Cycle 1 (within the first 4 weeks)
|
Number of Participants Reporting Adverse Events (AE)
Tijdsspanne: Throughout study duration and up to approximately 1 month after the last dosing cycle (Cycle 1 Day 1 to approximately 10 months)
|
Throughout study duration and up to approximately 1 month after the last dosing cycle (Cycle 1 Day 1 to approximately 10 months)
|
Number of Participants Discontinuing Due to AEs
Tijdsspanne: Throughout study duration (Cycle 1 Day 1 to approximately 9 months)
|
Throughout study duration (Cycle 1 Day 1 to approximately 9 months)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Best Overall Tumor Response
Tijdsspanne: 8 weeks
|
8 weeks
|
Maximum Concentration (Cmax) of Ridaforolimus
Tijdsspanne: Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1
|
Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1
|
Area Under the Curve (AUC[0 to Infinity]) of Ridaforolimus
Tijdsspanne: Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1
|
Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1
|
Apparent Terminal Half-Life (t1/2) of Ridaforolimus
Tijdsspanne: Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1
|
Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1
|
Clearance (CL) of Ridaforolimus
Tijdsspanne: Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1
|
Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1
|
Volume of Distribution at Steady State (Vss) of Ridaforolimus
Tijdsspanne: Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1
|
Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1
|
Phosphorylated 4E Binding Protein 1 (Phospho-4E-BP1) Blood Levels
Tijdsspanne: Screening, Cycle 1 Days 1, 2, 3, 6/7, 8; Cycle 2 Day 1
|
Screening, Cycle 1 Days 1, 2, 3, 6/7, 8; Cycle 2 Day 1
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Hart-en vaatziekten
- Vaatziekten
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Neoplasmata
- Lymfoproliferatieve aandoeningen
- Immunoproliferatieve aandoeningen
- Hematologische ziekten
- Hemorragische aandoeningen
- Hemostatische aandoeningen
- Paraproteïnemieën
- Bloed eiwit stoornissen
- Neoplasmata, plasmacel
- Multipel myeloom
- Fysiologische effecten van medicijnen
- Anti-infectieuze middelen
- Antineoplastische middelen
- Immunosuppressieve middelen
- Immunologische factoren
- Antibacteriële middelen
- Antibiotica, antineoplastiek
- Antischimmelmiddelen
- Sirolimus
Andere studie-ID-nummers
- 8669-001
- AP23573-02-101
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op ridaforolimus
-
Merck Sharp & Dohme LLCVoltooid
-
Medinol Ltd.Nog niet aan het wervenStenose van de popliteale arterie | Oppervlakkige stenose van de femorale arterie
-
Merck Sharp & Dohme LLCAriad PharmaceuticalsVoltooid
-
Medinol Ltd.Voltooidde Novo of Restenose LaesiesJapan
-
Medinol Ltd.Voltooid
-
Merck Sharp & Dohme LLCAriad PharmaceuticalsBeëindigd
-
Medinol Ltd.VoltooidMyocardiale ischemie | Hart-en vaatziekten | Hart-en vaatziekte | Coronaire stenoseIsraël
-
Medinol Ltd.WervingHart-en vaatziekten | Hart-en vaatziekte | Niet-ST verhoogd myocardinfarct | Coronaire stenoseIsraël, Brazilië